Michał Mazurek, MD; Gregory Y.H. Lip, MD
Mazurek M, Lip GY. In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y. Ann Intern Med. ;165:JC38. doi: 10.7326/ACPJC-2016-165-8-038
Download citation file:
Published: Ann Intern Med. 2016;165(8):JC38.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Prevention/Screening.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use